8-KLeadership ChangesExhibits & Filings

ECOLAB INC. 8-K Report, Executive Changes (Dec 8, 2022)

Filed December 8, 2022For Securities:ECL

Summary

Ecolab Inc. (ECL) announced on December 8, 2022, a significant addition to its Board of Directors with the appointment of Eric M. Green. Mr. Green brings extensive leadership experience, notably as President and CEO of West Pharmaceutical Services, Inc., and over two decades of experience at Sigma-Aldrich Corporation. His appointment is effective immediately, and he will serve on the Compensation and Human Capital Management Committee and the Governance Committee. This appointment signifies a strengthening of Ecolab's corporate governance and oversight. Investors can view Mr. Green's extensive background in the pharmaceutical and life sciences sectors as a valuable asset to Ecolab's strategic direction and executive compensation oversight. His participation in key board committees underscores the company's commitment to robust governance practices.

Key Highlights

  • 1Appointment of Eric M. Green to the Ecolab Board of Directors.
  • 2Mr. Green is the President and CEO of West Pharmaceutical Services, Inc.
  • 3Mr. Green has over 20 years of leadership experience at Sigma-Aldrich Corporation.
  • 4He will serve on the Compensation and Human Capital Management Committee.
  • 5He will also serve on the Governance Committee of the Board.
  • 6Mr. Green's appointment is effective December 8, 2022.
  • 7No reportable arrangements or understandings outside of standard director compensation.

Frequently Asked Questions

Eric M. Green is the current President and CEO of West Pharmaceutical Services, Inc., and has served as its Chair of the Board since May 2022. He also has over 20 years of experience in various leadership roles at Sigma-Aldrich Corporation. He will serve as a member of Ecolab's Compensation and Human Capital Management Committee and the Governance Committee.

Mr. Green's appointment adds significant leadership and industry expertise to Ecolab's Board of Directors. His experience, particularly in the pharmaceutical and life sciences sectors, is expected to provide valuable strategic insights and strengthen the company's governance, especially in areas of executive compensation and board oversight.

Mr. Green will participate in Ecolab’s regular director compensation arrangements. Details regarding this compensation are available in Ecolab's definitive proxy statement filed on March 18, 2022.

No, the filing explicitly states that there were no arrangements or understandings between Mr. Green and any other person regarding his election as a director, and there are no transactions requiring disclosure under Item 404(a) of Regulation S-K.